Sustainability Report (Chinese edition)

Overview

The report highlights Intech Biopharm's sustainability progress in 2024, emphasizing its leadership in respiratory medicine through the HFA MDI technology platform. Key financial achievements include an 8% revenue growth and a 20.5% increase in operating profit. Environmentally, the company achieved a 19.6% reduction in total waste and a 35% decrease in greenhouse gas emissions intensity. Socially, Intech maintained a 52% female workforce and actively participated in community health initiatives like blood donation drives. The company also successfully launched its first compound inhaler, Synbufo, in Taiwan and Macau, marking a significant milestone in its global expansion.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: Chinese
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services